Streetbeat News

Price Targets

OMQS

Lake Street analyst Jaeson Schmidt has maintained a 'Buy' rating on OMNIQ (NASDAQ:OMQS) but lowered the price target from $9 to $7.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 5:07 pm

HD

Guggenheim analyst Steven Forbes maintains a Buy rating on Home Depot (NYSE:HD) and raises the price target from $320 to $360.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 5:03 pm

XPOF

Guggenheim analyst John Heinbockel has maintained a 'Buy' rating on Xponential Fitness (NYSE:XPOF) but lowered the price target from $34 to $32.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 5:02 pm

SKY

Craig-Hallum analyst Greg Palm maintains a 'Buy' rating on Skyline Champion (NYSE:SKY) and raises the price target from $75 to $81.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 5:01 pm

SLND

Southland Holdings' stock has been downgraded from Buy to Neutral by DA Davidson, with a lowered price target from $12 to $7. Craig-Hallum also lowered its price target from $14 to $9.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 4:59 pm

ALC

Needham analyst David Saxon has reiterated a 'Buy' rating on Alcon (NYSE:ALC) and raised the price target from $94 to $98.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 4:56 pm

IOVA

Chardan Capital analyst Geulah Livshits has reiterated a 'Buy' rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a price target of $29.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 4:54 pm

CMRX

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Chimerix (NASDAQ:CMRX) and maintained an $11 price target.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 4:51 pm

SLND

Craig-Hallum analyst Christian Schwab maintains a 'Buy' rating on Southland Holdings (AMEX:SLND) but has lowered the price target from $14 to $9.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 4:45 pm

GEHC

Wells Fargo has initiated coverage on GE HealthCare Technologies Inc (NASDAQ:GEHC) with an Overweight rating and a price target of $90. The analyst believes GEHC is well-positioned to capitalize on the recent approval of Alzheimer's drugs, which should drive demand for imaging equipment. However, risks include increased competition, slower-than-expected uptake of new product launches, inflationary and supply chain headwinds, a slowdown in procedure volumes, and China volume-based procurement risk.

Portfolio Pulse from Vandana Singh

August 16, 2023 | 4:42 pm